In the DEA's view, the fact that most states allow patients to use marijuana for symptom relief is irrelevant.
The case is the latest example of people who say their savings were seized in airports, despite it being perfectly legal to fly domestically with large amounts of cash.
Plus: 88,000 New Jersey marijuana cases dismissed, Slate looks inside the conservative publishing industry, and more...
The 9th Circuit Considers Whether the DEA's Classification of Marijuana Violates Federalism and the Separation of Powers
The puzzle of marijuana's Schedule I status invites a reconsideration of the agency's vast discretion to decide which substances should be prohibited.
A Twitter Tiff Between Former Federal Health Officials Highlights the Weakness of the Case for Banning Kratom
Former Assistant Secretary for Health Brett Giroir says former FDA Commissioner Scott Gottlieb's support for a ban was based on "embarrassingly poor evidence."
In 2014, Reason reported on the misbehavior of Rod Ponton, who has suddenly risen to internet stardom after being unable to turn off an adorable filter during an online legal case.
After the DEA Robbed Her of $43,000 at an Airport, She Joined a Class Action Challenging the Agency's Cash Grabs
The lawsuit argues that the DEA is violating the Fourth Amendment by seizing money from travelers without evidence of criminal activity.
A Formerly Secret Memo Explains the DEA's Long Delay in Approving New Producers of Marijuana for Research
The Justice Department concluded in 2018 that an anti-drug treaty requires stricter controls than the DEA originally planned.
A class-action lawsuit is now challenging the DEA's habit of seizing large amounts of cash from travelers without evidence of any crime.
CTPharma's collaboration with Yale researchers seems to be the first clinical trial involving U.S.-grown marijuana that is not supplied by the federal government.
Former DEA special agent Chad Scott has been convicted of perjury, obstruction of justice, and falsifying government records.
The agency takes one small, mostly symbolic step for kind bud.
After nearly three years of ghosting research cannabis applicants, the DEA has 30 days to explain its inaction.
An ACLU brief bolsters the state's case, arguing that people reasonably expect information about the medications they take will be kept confidential.
Philadelphia's innovative treatment program for incarcerated opioid users is failing. Is it because doctors don't want to treat opioid addicts?
Cannabidiol is caught between two worlds.
The number of past-month users was up last year from 2016, but it was still lower than in several previous years.
The FDA approved Epidiolex in June, and today the DEA made it a Schedule V drug, the least restrictive classification for controlled substances.
Does anyone actually call weed "shoe"?
Two years after accepting applications, the DEA has yet to grant licenses to growers.
The attorney general claims that approving new producers of cannabis might violate anti-drug treaties.
The Feds Are Willing to Let More Medical Workers Treat Opioid Addicts. Now the States Need to Step Up and Allow It.
It's time we unleashed non-physicians to help opioid addicts.
"DEA's use of proceeds acquired through civil asset forfeiture to expand marijuana enforcement makes the already unacceptable practice even worse."
"This use of secret evidence may be occurring regularly in cases throughout the country."
Search warrant lists probable cause for distribution and possession with intent to distribute a controlled substance and health care fraud.
Gottlieb isn't a perfect harm reduction advocate, but he's a hell of a lot better than the D.C. status quo.
Do the pain relief benefits of prescription opioids outweigh their addiction risks?
Seize the drugs. Sell the drugs. Arrest the buyers. Repeat.
Acting DEA Administrator Chuck Rosenberg reportedly resigned in part over the Justice Department's obstruction of marijuana research.
"I take the Hippocratic oath seriously that my job is to relieve pain and suffering," says Dr. Forest Tennant, a California pain specialist who patients from across the nation are flocking to see.
A new government watchdog report finds the DEA grabs cash just for the sake of grabbing cash, raising civil liberties concerns.
Doctors using DEA-approved marijuana find it is useless for research purposes.
The DEA's backtracking underlines the arbitrariness of the government's pharmacological taboos.
After backlash, they've extended the comment period and called for FDA input.
One informant lied in court and still worked for the DEA, pocketing over $469,000 in a five-year span.
After meeting with the DEA administrator, Rep. Mark Pocan says the agency may allow for more public comment on whether to make Kratom a Schedule I drug.